EMN
70
-2
M
14
2
AKAM
56
-2
GOOG
63
2
CME
56
-3
TSCO
55
-2
FAST
46
-2
UNP
48
-2
IFF
60
-3
ABT
57
-9
PPL
60
-7
HSIC
56
3
ADSK
65
-2
WU
16
2
ICE
64
-5
SHW
71
-2
BF.B
57
7
VRSK
35
-3
LMT
40
-5
DOV
63
-6
EMN
70
-2
M
14
2
AKAM
56
-2
GOOG
63
2
CME
56
-3
TSCO
55
-2
FAST
46
-2
UNP
48
-2
IFF
60
-3
ABT
57
-9
PPL
60
-7
HSIC
56
3
ADSK
65
-2
WU
16
2
ICE
64
-5
SHW
71
-2
BF.B
57
7
VRSK
35
-3
LMT
40
-5
DOV
63
-6
Financhill
Back

Editas Medicine 10K Form

Sell
40

EDIT
Editas Medicine

Last Price:
3.92
Seasonality Move:
2.24%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive EDIT News And Ratings

See the #1 stock for the next 7 days that we like better than EDIT

EDIT Financial Statistics

Sales & Book Value

Annual Sales: $78.12M
Cash Flow: $-60.56M
Price / Cash Flow: 0
Annual Sales: $2.81
Price / Book: 1.38

Profitability

EPS (TTM): -2.36000
Net Income (TTM): $-193.45M
Gross Margin: --
Return on Equity: -59.13%
Return on Assets: -40.8%

Editas Medicine Earnings Forecast

Key Editas Medicine Financial Ratios

  • The Research & Development expenses have been 227.40% of Revenue.
  • The Interest Expense is 5.47% of Operating Income.
  • The Net Earning history of EDIT is -196.13% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 4 years.

Editas Medicine Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: EDIT
CUSIP: 28106W
Website: editasmedicine.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.85
Quick Ratio: 3.76

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EDIT Technical Analysis vs Fundamental Analysis

Sell
40
Editas Medicine (EDIT) is a Sell

Is Editas Medicine a Buy or a Sell?

  • Editas Medicine stock is rated a Sell
    The current Editas Medicine [EDIT] share price is $3.87. The Score for EDIT is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.